Oppenheimer analyst Yigal Nochomovitz maintained an Outperform rating on Bio Blast Pharma Ltd (NASDAQ:ORPN) with a price target of $32, after the company announced positive …
Oppenheimer analyst Yigal Nochomovitz maintained an Outperform rating on Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) with a price target of $11, which represents a potential …
In a research report issued today, Oppenheimer analyst Yigal Nochomovitz reiterated a Perform rating on Galena Biopharma (NASDAQ:GALE), following the company’s third-quarter earnings. …
In a research report issued to investors Wednesday, Oppenheimer analyst Yigal Nochomovitz reiterated a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), following the company’s third-quarter …
Oppenheimer analyst Yigal Nochomovitz initiated an Outperform rating on Vascular Biogenics (NASDAQ:VBLT) with a $16 price target, which implies an upside of 144% from current levels. Nochomovitz …
In a report sent to investors today, Oppenheimer analyst Yigal Nochomovitz maintained a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), following the positive FDA advisory panel …
In a research report issued today, Oppenheimer analyst Yigal Nochomovitz maintained a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), while no price target was provided. Nochomovitz …
